Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3.
about
Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritisExpression and functional properties of antibodies to tissue inhibitors of metalloproteinases (TIMPs) in rheumatoid arthritisProgress in matrix metalloproteinase research.TIMP3: a physiological regulator of adult myogenesis.Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression.Consistent DNA hypermethylation patterns in laryngeal papillomas.A question of transformation: the synovial fibroblast in rheumatoid arthritis1.5 Decades Later: Bearing fruits from the ACR/EULAR exchange ProgramMetalloproteinases, inflammation, and rheumatoid arthritis.Enhanced expression of tissue inhibitor of metalloproteinases-4 gene in human osteoarthritic synovial membranes and its differential regulation by cytokines in chondrocytesGene therapy for autoimmune diseases: quo vadis?Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.What are the roles of metalloproteinases in cartilage and bone damage?Are fibroblasts involved in joint destruction?Proteinases in the joint: clinical relevance of proteinases in joint destructionSynovial fibroblasts: key players in rheumatoid arthritis.Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts.Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Metalloproteases as potential therapeutic targets in arthritis treatment.PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysisNovel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis.Management of knee osteoarthritis. Current status and future trends.Establishment of an in vitro three-dimensional model for cartilage damage in rheumatoid arthritis.TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors.Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis.Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts.Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy.Evaluation on Cartilage Morphology after Intra-Articular Injection of Titanium Dioxide Nanoparticles in Rats
P2860
Q24796801-1D8ECC5F-E290-4502-855C-8B0C47928C42Q24799214-1AEAB809-8234-460A-BA54-EC0085BD8962Q24812237-BA62A3E4-672B-4089-923C-FB42D4AB3F37Q33608536-A9C60D49-E421-4C0A-B028-C7D96DAF8D98Q34072911-02BEBEFF-E68B-4FC4-9A29-A04A65962893Q34447966-4B407833-3F59-466F-A97E-F8F4C96FF542Q34991014-8DC711B3-2398-4120-B523-576FAA6130D5Q35111655-CDD5663C-83E5-4441-9A4A-CE988A506880Q35147591-A073FAE2-A10D-4D6E-A58F-20C0290FBA54Q35553483-A9C6A6B5-F846-4639-81F2-E92B61F01A56Q35631999-452F7BF0-E80C-4B52-A853-9212534ED909Q35906093-3CE44A07-D39B-4044-991B-50F13779155EQ36009930-7E8DB280-111D-4190-94FA-AB2660F054E5Q36292638-37251992-86A5-4863-BC81-6F54771168B6Q36292643-2AB8A01F-E9FB-4CD9-8515-5BC2B3BB0BB7Q36401848-9C0947E8-C86E-4B1C-86BB-C3DD3EB9EAC9Q36433286-30BDEDAD-19F9-48F4-AD3C-F36845A2275BQ36465510-79F81607-6773-4AC3-8A5E-F4652D488A9FQ36644577-253284B6-2892-4D89-9803-2D9B4C4C91FBQ37030862-234826A6-ECCD-43DE-9F4F-CA16F2DD66F1Q37345108-8AF5DF12-BF0D-4BAA-A19C-ED7005DD52A8Q37596543-110559BC-A9D9-4261-BC46-1991F1F8A5D5Q37813237-95612ADF-81BA-4CDB-B3B1-CCC28C5B1132Q38822218-0D736DC9-3ED2-4D00-A1F8-0DEC828E0B94Q39024735-D1EFAD0E-B62B-4FBE-BA6B-AE629A1E2020Q40607415-46D5E219-AB2D-42B0-BFFB-07BB7FBDACEDQ44911297-8D0E9D63-0F1E-4C72-BC54-13E4CDE0D478Q47223491-C0BAF1D4-AFA0-489B-8940-242BD0A4E6F9Q47596891-A7244E6D-5C39-4C9F-AC10-CFF8A53EA383Q50916304-0D00F355-F18B-4087-87AB-892C7CF35938Q51363157-1572625B-21B4-4866-9647-7680269DA05BQ58909790-8B09905C-77F0-411E-B269-EE0300D36677
P2860
Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@en
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@nl
type
label
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@en
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@nl
prefLabel
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@en
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@nl
P2093
P2860
P356
P1433
P1476
Cartilage degradation and inva ...... transfer of TIMP-1 and TIMP-3.
@en
P2093
Breedveld FC
Grimbergen JM
Huisman LG
Huizinga TW
Pieterman EJ
Seemayer CA
Verheijen JH
P2860
P2888
P304
P356
10.1038/SJ.GT.3301871
P50
P577
2003-02-01T00:00:00Z
P5875
P6179
1038777803